| Dr Firooezh Motamedi, MD | |
|
3033 Bunker Hill St, Suite 310, San Diego, CA 92109-5705 | |
| (619) 528-5000 | |
| Not Available |
| Full Name | Dr Firooezh Motamedi |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 32 Years |
| Location | 3033 Bunker Hill St, San Diego, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285720227 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | A87419 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital - Zion | San diego, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern California Permanente Medical Group | 6002729175 | 7951 |
News Archive
Beth Israel Deaconess Medical Center has been awarded a grant from the National Institutes of Health to investigate the use of a new noninvasive neurophysiologic intervention for the treatment of patients with spinal cord injuries.
A new screening test for oesophageal (food pipe) cancer could dramatically improve survival from the disease, according to research published in the British Journal of Cancer this week.
The growing numbers of new cases of substance abuse disorders are perplexing. After all, the course of drug addiction so often ends badly. The negative consequences of drug abuse appear regularly on TV, from stories of celebrities behaving in socially inappropriate and self-destructive ways while intoxicated to dramatization of the rigors of drug withdrawal on "Intervention" and other reality shows.
Chagas disease is one of the most deadly parasitic diseases in the world. It affects more than 10 million people, primarily in the Americas. In South America alone it kills 50 000 people each year. A reliable and rapid diagnosis is the key in the battle against infection but until now, this has been next to impossible.
Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today announced that first patients were enrolled in the MARINE and ANCHOR Phase 3 clinical trials for AMR101, the Company's lead product candidate. These clinical trials are designed to demonstrate that AMR101 lowers triglyceride levels in patients with very high triglycerides (the MARINE Study) and high triglycerides in patients with mixed dyslipidemia being treated with statins (the ANCHOR Study).
› Verified 1 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
Beth Israel Deaconess Medical Center has been awarded a grant from the National Institutes of Health to investigate the use of a new noninvasive neurophysiologic intervention for the treatment of patients with spinal cord injuries.
A new screening test for oesophageal (food pipe) cancer could dramatically improve survival from the disease, according to research published in the British Journal of Cancer this week.
The growing numbers of new cases of substance abuse disorders are perplexing. After all, the course of drug addiction so often ends badly. The negative consequences of drug abuse appear regularly on TV, from stories of celebrities behaving in socially inappropriate and self-destructive ways while intoxicated to dramatization of the rigors of drug withdrawal on "Intervention" and other reality shows.
Chagas disease is one of the most deadly parasitic diseases in the world. It affects more than 10 million people, primarily in the Americas. In South America alone it kills 50 000 people each year. A reliable and rapid diagnosis is the key in the battle against infection but until now, this has been next to impossible.
Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today announced that first patients were enrolled in the MARINE and ANCHOR Phase 3 clinical trials for AMR101, the Company's lead product candidate. These clinical trials are designed to demonstrate that AMR101 lowers triglyceride levels in patients with very high triglycerides (the MARINE Study) and high triglycerides in patients with mixed dyslipidemia being treated with statins (the ANCHOR Study).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Firooezh Motamedi, MD 3033 Bunker Hill St, San Diego, CA 92109-5705 Ph: (619) 528-5000 | Dr Firooezh Motamedi, MD 3033 Bunker Hill St, Suite 310, San Diego, CA 92109-5705 Ph: (619) 528-5000 |
News Archive
Beth Israel Deaconess Medical Center has been awarded a grant from the National Institutes of Health to investigate the use of a new noninvasive neurophysiologic intervention for the treatment of patients with spinal cord injuries.
A new screening test for oesophageal (food pipe) cancer could dramatically improve survival from the disease, according to research published in the British Journal of Cancer this week.
The growing numbers of new cases of substance abuse disorders are perplexing. After all, the course of drug addiction so often ends badly. The negative consequences of drug abuse appear regularly on TV, from stories of celebrities behaving in socially inappropriate and self-destructive ways while intoxicated to dramatization of the rigors of drug withdrawal on "Intervention" and other reality shows.
Chagas disease is one of the most deadly parasitic diseases in the world. It affects more than 10 million people, primarily in the Americas. In South America alone it kills 50 000 people each year. A reliable and rapid diagnosis is the key in the battle against infection but until now, this has been next to impossible.
Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today announced that first patients were enrolled in the MARINE and ANCHOR Phase 3 clinical trials for AMR101, the Company's lead product candidate. These clinical trials are designed to demonstrate that AMR101 lowers triglyceride levels in patients with very high triglycerides (the MARINE Study) and high triglycerides in patients with mixed dyslipidemia being treated with statins (the ANCHOR Study).
› Verified 1 days ago
Dr. Ramin Motarjemi, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 200 W Arbor Dr, San Diego, CA 92103 Phone: 858-249-2500 Fax: 858-657-8069 | |
Dr. Shweta Warner, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 4647 Zion Ave, San Diego, CA 92120 Phone: 619-221-6258 Fax: 619-221-6012 | |
Dr. Matthew James Roosevelt, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 4647 Zion Ave, Department Of Hospital Medicine, San Diego, CA 92120 Phone: 619-952-5091 | |
Dr. Daniel Joseph Desantis, MD Rheumatology Medicare: Medicare Enrolled Practice Location: Naval Medical Ctr, 34800 Bob Wilson Dr., San Diego, CA 92134 Phone: 619-532-7935 | |
Kris Kumar, Rheumatology Medicare: Medicare Enrolled Practice Location: 200 W Arbor Dr, San Diego, CA 92103 Phone: 800-926-8273 Fax: 888-539-8781 | |
Jedidiah Daniel Bell, Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 200 W Arbor Dr, San Diego, CA 92103 Phone: 619-471-0434 | |
Dr. Umber Dube, MD PHD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 8899 University Center Lane, Suite 350 Mc 0975, San Diego, CA 92122 Phone: 858-657-1675 |